Reason for request
Extension of the indication
Clinical Benefit
Clinical Added Value
| moderate |
Given the efficacy of VOTUBIA (everolimus) in reducing renal angiomyolipoma volume associated with tuberous sclerosis complex in adult patients, VOTUBIA provides a substantial improvement in actual benefit (IAB III) in the treatment of patients not requiring immediate surgery (nephrectomy or embolisation). |
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
Brm02AUXJp9HZEtV
